Jefferies Financial Group Initiates Coverage on Vor Biopharma (NASDAQ:VOR)

Analysts at Jefferies Financial Group began coverage on shares of Vor Biopharma (NASDAQ:VOR) in a research note issued to investors on Monday. The brokerage set a “buy” rating and a $50.00 price target on the stock. Jefferies Financial Group’s price objective suggests a potential upside of 245.30% from the company’s current price.

Other research analysts have also issued reports about the company. JPMorgan Chase & Co. decreased their price objective on Vor Biopharma from $43.00 to $40.00 and set an “overweight” rating on the stock in a report on Friday, December 19th. Wells Fargo & Company initiated coverage on shares of Vor Biopharma in a research report on Thursday, March 19th. They issued an “overweight” rating and a $30.00 target price for the company. Citigroup assumed coverage on shares of Vor Biopharma in a research note on Friday, January 9th. They issued a “buy” rating and a $50.00 price target on the stock. TD Cowen initiated coverage on shares of Vor Biopharma in a research report on Wednesday, December 17th. They set a “buy” rating on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Vor Biopharma in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $49.89.

Vor Biopharma Stock Performance

Vor Biopharma stock opened at $14.48 on Monday. The company has a market capitalization of $150.74 million, a price-to-earnings ratio of -0.04 and a beta of 1.99. Vor Biopharma has a 12 month low of $2.62 and a 12 month high of $65.80. The stock’s 50 day moving average is $14.21 and its 200-day moving average is $18.00.

Institutional Trading of Vor Biopharma

Large investors have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. acquired a new position in shares of Vor Biopharma during the fourth quarter worth $36,000. Goldman Sachs Group Inc. boosted its holdings in shares of Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after acquiring an additional 58,247 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Vor Biopharma during the 2nd quarter valued at $66,000. Chung Wu Investment Group LLC bought a new stake in Vor Biopharma during the 4th quarter worth $109,000. Finally, Susquehanna Portfolio Strategies LLC acquired a new position in Vor Biopharma in the 4th quarter worth about $134,000. 97.29% of the stock is owned by institutional investors and hedge funds.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).